Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...
Adcentrx Therapeutics To Showcase Novel STEAP1 And Napi2b Adcs With Oral And Poster Presentations At AACR 2025
The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...
Forbes29d
A New Approach To Childhood Neuroblastoma
The current treatment for neuroblastoma relies on topoisomerase inhibitors, which disrupt DNA replication. While these drugs can induce remission, long-term survival rate remains unfavorable.
Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript
MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...
GlobalData on MSN4d
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...
American Association of Individual Investors2d
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 12.85%
MacroGenics, Inc.’s MGNX share price has dipped by 12.85%, which has investors questioning if this is right time to buy.
Taiwan News2d
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights
In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...
BioSpace4d
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...